Abbott Laboratories (FRA:ABL)
Germany · Delayed Price · Currency is EUR | Market Cap | 188.23B |
| Revenue (ttm) | 37.37B |
| Net Income (ttm) | 11.87B |
| Shares Out | n/a |
| EPS (ttm) | 6.78 |
| PE Ratio | 15.86 |
| Forward PE | 22.52 |
| Dividend | 2.11 (1.93%) |
| Ex-Dividend Date | Oct 15, 2025 |
| Volume | 80 |
| Average Volume | 69 |
| Open | 108.22 |
| Previous Close | 108.82 |
| Day's Range | 108.22 - 109.34 |
| 52-Week Range | 103.84 - 133.78 |
| Beta | n/a |
| RSI | 54.43 |
| Earnings Date | Jan 22, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial numbers in USD Financial StatementsNews
Abbott Laboratories's Latest Glucose Sensor Is Now Publicly Funded In Canada
(RTTNews) - Abbott Laboratories (ABT), Wednesday announced that its sensor-based glucose technology, the FreeStyle Libre 3 Plus sensor, is now publicly funded in every province across Canada, meaning ...
Abbott: Not Cheap, But Built To Compound In Uncertain Markets
Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Li...
Sentinel Net Lease: Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy
The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties. LAS VEGAS, NEVADA / ACCESS Newswire / January 7, 2026 / Sentinel Net Le...
Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy
The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties. LAS VEGAS, NEVADA / ACCESS Newswire / January 7, 2026 / Sentinel Net Lease...
Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy
The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties. LAS VEGAS, NEVADA / ACCESS Newswire / January 7, 2026 / Sentinel Net Lease...
Abbott hosts conference call for fourth-quarter earnings
ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.
Barclays Maintains Overweight Rating on Abbott Laboratories (ABT) with Revised Price Target | ...
Barclays Maintains Overweight Rating on Abbott Laboratories (ABT) with Revised Price Target | ABT Stock News
Abbott Laboratories Launches Libre Assist To Deliver Personalized Meal Guidance
(RTTNews) - Abbott Laboratories (ABT), Monday announced the launch of Libre Assist, a new feature within the Libre app designed to help people with diabetes in the U.S.
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions
Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist1 leverages AI to predict how food choice...
2 Healthcare Stocks to Buy in a Bear Market
Johnson & Johnson and Abbott Laboratories are diversified healthcare companies with attractive prospects. Both have raised their dividends for over 50 consecutive years.
Best Dividend Aristocrats For January 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%...
Best Dividend Kings: December 2025
Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long...
Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January
Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite...
Abbott Laboratories Shrugs Off Tariffs And China Headwinds With A 7% Dividend Raise
FDA Clears Abbott's Volt PFA System For AFib, Expanding US Treatment Options
On Monday, the U.S. Food and Drug Administration (FDA) approved Abbott Laboratories’ (NYSE: ABT) Volt PFA System to treat patients battling atrial fibrillation (AFib) . AFib is the most common type o...
Abbott Laboratories (ABT) Gains FDA Approval for Volt PFA System
Abbott Laboratories (ABT) Gains FDA Approval for Volt PFA System
Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation
Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PF...
Interesting ABT Put And Call Options For August 2026
Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is...
Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart
First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise placemen...
2 Dividend Stocks to Buy for 2026 and Beyond
CVS Health is slowly righting the ship after several challenging years. Abbott Laboratories' strong business should improve thanks to an acquisition.
Abbott Laboratories (ABT) Shares Cross 2% Yield Mark
Looking at the universe of stocks we cover at Dividend Channel, in trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (an...
Chris Blumas' Top Picks: Constellation Software, Brookfield Infrastructure & Abbott Labs
Chris Blumas, portfolio manager at Raymond James Investment Counsel, shares his top stock picks to watch in the market.
Abbott Laboratories (ABT) Declares Quarterly Dividend
Abbott Laboratories (ABT) Declares Quarterly Dividend
Abbott Laboratories declares $0.063 dividend
Abbott Laboratories announces $0.063/share dividend with 0.2% yield. Key dates inside.
Start the New Year Off With Passive Income: 3 Dividend Kings to Buy Now
Dividend stocks may boost your portfolio during any market environment. These particular companies have shown their commitment to dividend payments and growth over time.